Today's news

A new clinical trial for the investigational compound GSK2402968 (formerly PRO051) was posted to www.clinicaltrials.gov today. This study, GSK protocol # DMD114118, will assess the pharmacokinetics, safety and tolerability of GSK2402968 after a single administration, at escalating dose levels, in non-ambulatory boys with DMD who have a dystrophin gene mutation amenable to an exon 51 skip.

The inclusion/exclusion criteria, study endpoints and investigator locations are posted on the website.

As the clinical development program advances, further clinical trials will be posted to www.clinicaltrials.gov. We will alert you when this happens.

Questions which are not answered by the information on www.clinicaltrials.gov should be sent to:

John E. Kraus, MD, PhD Padraig Wright, MD, PhD

john.e.kraus@gsk.com padraig.x.wright@gsk.com

Favorite

0 members favorited this

Comment

You need to be a member of PPMD Community to add comments!

Join PPMD Community

Comment by cheryl cliff on June 8, 2010 at 7:41pm: I've no official idea Mindy, but expect most or all suppliments are taboo prior to and during most clinical trials. At least that's the way they've done things in the past. I presume pharma's would rather have their participants steriod naive if they had the chance.

Comment by Mindy on June 8, 2010 at 5:06pm: Anyone have any idea on whether the ambulatory study will forbid CoQ10? I think most boys are on it...

Comment by cheryl cliff on May 24, 2010 at 7:24pm: Sadly, we won't be able to attend this years conference in Denver. So close to home and what looks like a fantastic adjenda!! Very frustrating.